139,600 Shares in Vor Biopharma Inc. $VOR Acquired by OMERS ADMINISTRATION Corp

Key Points

• OMERS ADMINISTRATION Corp acquired 139,600 shares of Vor Biopharma Inc. valued at approximately $100,000, marking a small ownership stake of about 0.11% in the company.
• Recent trades indicate significant activity among institutional investors, with Northern Trust Corp increasing its holdings by 39% and Money Concepts Capital Corp boosting theirs by over 106% during the first quarter.
• Vor Biopharma's stock has seen volatility, currently trading around $1.93, with an annual range between $0.13 and $3.29, and analysts rating the stock as a "Moderate Buy" with an average target price of $6.07.

OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma Inc. (NYSE:VOR - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 139,600 shares of the company's stock, valued at approximately $100,000. OMERS ADMINISTRATION Corp owned about 0.11% of Vor Biopharma at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of VOR. Trustees of Columbia University in the City of New York acquired a new position in Vor Biopharma in the fourth quarter valued at about $102,000. Northern Trust Corp lifted its position in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after buying an additional 44,252 shares during the last quarter. Money Concepts Capital Corp lifted its position in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after buying an additional 25,930 shares during the last quarter. Institutional investors and hedge funds own 97.29% of the company's stock.

Vor Biopharma Stock Down 10.4%

NYSE:VOR traded down $0.21 on Wednesday, reaching $1.80. 6,041,745 shares of the company's stock were exchanged, compared to its average volume of 7,646,274. The firm has a market capitalization of $228.03 million, a price-to-earnings ratio of -1.09 and a beta of 2.05. The business has a fifty day moving average of $2.12 and a 200-day moving average of $1.12. Vor Biopharma Inc. has a 52-week low of $0.13 and a 52-week high of $3.29.

Insider Transactions at Vor Biopharma

In other Vor Biopharma news, major shareholder Reprogrammed Interchange Llc sold 350,000 shares of the business's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $1.82, for a total transaction of $637,000.00. Following the sale, the insider directly owned 34,213,292 shares in the company, valued at $62,268,191.44. This represents a 1.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 4,760,809 shares of company stock worth $9,493,659 in the last 90 days. 0.45% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on VOR. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $6.07.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.